[O14] Oral Session 14　婦人科
【E】

[O14-1] Pembrolizumab + Chemotherapy in Japanese Patients With Persistent, Recurrent, or Metastatic Cervical Cancer: KEYNOTE-826

^○Kan Yonemori¹, Shin Nishio², Tomoka Usami³, Shinichiro Minobe⁴, Mayu Yunokawa⁵, Takashi Iwata⁶, Aikou Okamoto⁷, Yoichi Aoki⁸, Hiroaki Itamochi⁹, Munetaka Takekuma¹⁰, Kenichi Harano¹¹, Keiko Yamamoto¹², Hiroyuki Ugai¹², Cumhur Tekin¹³, Sarper Toker¹³, Nicoletta Colombo¹⁴, Keiichi Fujiwara¹⁵, Kosei Hasegawa¹⁵ (1.Department of Medical Oncology, National Cancer Center Hospital, 2.Kurume University Hospital, Fukuoka, Japan, 3.Ehime University Hospital, Ehime, Japan, 4.Hokkaido Cancer Center, Hokkaido, Japan, 5.Cancer Institute Hospital of JFCR, Tokyo, Japan, 6.Keio University Hospital, Tokyo, Japan, 7.The Jikei University Hospital, Tokyo, Japan, 8.University of the Ryukyus Hospital, Okinawa, Japan, 9.Iwate Medical University Hospital, Iwate, Japan, 10.Shizuoka Cancer Center, Shizuoka, Japan, 11.National Cancer Center Hospital East, Kashiwa, Japan, 12.MSD K.K., Tokyo, Japan, 13.Merck & Co., Inc., Kenilworth, NJ, USA, 14.European Institute of Oncology IRCCS and Università degli Studi di Milano Bicocca, Milan, Italy, 15.Saitama Medical University International Medical Center, Saitama, Japan)